Complete response is reversible upon vismodegib withdrawal and re‐inducible upon vismodegib re‐administration in a patient with locally advanced BCC

Abstract

Recurrence after the discontinuation of Hedgehog pathway inhibitor (HPI) treatment in responding patients with advanced basal cell carcinoma (BCC) is an emerging clinical challenge. A 54‐year old female patient presented in 2016 with an histologically proven BCC on the right peri‐auricular area, extending to the ear, that was present for 6 years (Figure 1, upper panel). Due to considerable deformity expected with surgery, the patient was treated with vismodegib 150 mg/day.

This article is protected by copyright. All rights reserved.

http://bit.ly/2W1ANaP